Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V0KJ
|
|||
| Former ID |
DCL001110
|
|||
| Drug Name |
IDDBCP161883
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [1] | |
| Company |
Mitsubishi Tanabe
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01798238) Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 2 | Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95. | |||
| REF 3 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.